Mereo BioPharma Group - - 6 Year Stock Price History | MREO

The latest closing stock price for Mereo BioPharma Group - as of May 30, 2025 is 2.15.

  • An investor who bought $1,000 worth of Mereo BioPharma Group - stock at the IPO in 2019 would have $-669 today, roughly -1 times their original investment - a -16.84% compound annual growth rate over 6 years.
  • The all-time high Mereo BioPharma Group - stock closing price was 6.50 on April 24, 2019.
  • The Mereo BioPharma Group - 52-week high stock price is 5.02, which is 133.5% above the current share price.
  • The Mereo BioPharma Group - 52-week low stock price is 1.57, which is 27% below the current share price.
  • The average Mereo BioPharma Group - stock price for the last 52 weeks is 3.42.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.

Mereo BioPharma Group - - 6 Year Stock Price History | MREO

  • An investor who bought $1,000 worth of Mereo BioPharma Group - stock at the IPO in 2019 would have $-669 today, roughly -1 times their original investment - a -16.84% compound annual growth rate over 6 years.
  • The all-time high Mereo BioPharma Group - stock closing price was 6.50 on April 24, 2019.
  • The Mereo BioPharma Group - 52-week high stock price is 5.02, which is 133.5% above the current share price.
  • The Mereo BioPharma Group - 52-week low stock price is 1.57, which is 27% below the current share price.
  • The average Mereo BioPharma Group - stock price for the last 52 weeks is 3.42.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$209.6B
Amgen (AMGN)$149.1B
Gilead Sciences (GILD)$130.2B
Vertex Pharmaceuticals (VRTX)$125.6B
Bristol Myers Squibb (BMY)$100.2B
CSL (CSLLY)$74.3B
GSK (GSK)$74.1B
Regeneron Pharmaceuticals (REGN)$61.6B
Argenex SE (ARGX)$36.2B
Alnylam Pharmaceuticals (ALNY)$30.5B
BioNTech SE (BNTX)$23.7B
BeiGene (ONC)$22.8B
Biogen (BIIB)$17.4B
Genmab (GMAB)$13.3B
Genmab (GNMSF)$13.3B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.3B
Illumina (ILMN)$11.3B
Incyte (INCY)$11.3B
Ascendis Pharma (ASND)$10.1B
Exelixis (EXEL)$10B
Swedish Orphan Biovitrum (BIOVF)$9.6B
Moderna (MRNA)$9.6B
QIAGEN (QGEN)$9B
Exact Sciences (EXAS)$7.7B
Bio-Techne Corp (TECH)$7.6B
Repligen (RGEN)$7.3B
Halozyme Therapeutics (HALO)$7.3B
Roivant Sciences (ROIV)$7.2B
Revolution Medicines (RVMD)$6.8B